Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services Beltsville, MD, USA / Yokohama, Japan – 3rd March 2026 Bioserve – A REPROCELL Company proudly announces the launch of US FDA-compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing services for human induced pluripotent stem cells (iPSCs), now available to support global…
January 28th, 2026 – REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL’s StemRNA™ Clinical…
Yokohama, Japan / Bilbao, Spain – October 20th — REPROCELL (Yokohama, Japan; TYO: 4978) and Histocell (Bilbao, Spain) are proud to announce that the Spanish Agency for Medicines and Medical Devices (AEMPS), operating under European Medicines Agency (EMA) oversight, has granted to Histocell Good Manufacturing Practice (GMP) certificate and authorization of the manufacturing process of induced Pluripotent…
Yokohama, Japan, August 20, 2025 REPROCELL is proud to announce the introduction of NeoSight – Neoantigen Detection Service, a state-of-the-art, end-to-end platform designed to empower researchers and clinicians with high-confidence neoantigen data for personalized immuno-oncology applications. This service integrates Next Generation Sequence (NGS) data obtained from whole exome sequencing (WES) of tumor and matched normal…
Glasgow, UK — Scientists from REPROCELL Europe, working in collaboration with researchers at Durham University, have successfully developed a full-thickness human skin model using fibroblasts derived from induced pluripotent stem cells (iPSCs). The breakthrough, published in Cells (14(14):1044, 2025), demonstrates a novel approach to producing consistent, high-quality human skin constructs for research and therapeutic applications. Current skin models…
Hyderabad, India: Bioserve Biotechnologies India Pvt. Ltd. has entered into an exclusive distribution agreement with HLB PEP Co., Ltd. (Republic of Korea) for the Indian market. Under this agreement, Bioserve will begin distributing peptides manufactured by HLB PEP. Bioserve is a leading provider of DNA synthesis and genetic analysis services in India. Since its establishment, the…
YOKOHAMA, Japan – April 25, 2025 – REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc. (Headquarters: Taiwan; hereinafter “Steminent”), reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy “Stemchymal®” (hereinafter “Stemchymal”). REPROCELL holds the exclusive commercialization license agreement for Stemchymal in…
REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology. This major medical advancement marks a pivotal breakthrough in redefining women’s healthcare, supported by our StemRNA™ Clinical induced Pluripotent Stem Cells (iPSCs).
Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture Cambridge, UK and Yokohama, Japan – Qkine Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, and REPROCELL Inc., Japan’s first and leading induced pluripotent stem cell (iPSC) company, have partnered to globally…
Hyderabad, India – 22nd July 2024 – Bioserve India is excited to announce the launch of its advanced stem cell products in India. These new products from REPROCELL aims to support innovation in scientific research and drug development, supporting advancements in regenerative medicine and therapeutic discovery in Indian Market. The stem cell market is a rapidly growing industry that encompasses a wide range of services and products. Within the stem cell market, numerous industries are engaged in critical activities such as research and development manufacturing, and distribution of stem cell therapy products.